



## Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Friday, 15 September 2017

Radebeul, Germany & Lyon, France, September 15, 2017 -- **RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOVA, a pharmaceutical establishment for experimental drug products, today announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM<sup>®</sup>, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.**

Manufacturing has been performed with the patented process TENPORA<sup>®</sup> of RIBOXX in full compliance with the EU GMP requirements, and with the GMP specifications of the experimental drug.

RIBOXXIM<sup>®</sup> is a proprietary drug substance of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology with the historical TLR3 ligand poly(I:C) and its derivatives.

RIBOXXIM<sup>®</sup> has been validated in multiple pre-clinical studies for immunotherapy of cancer. It displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. RIBOXXIM<sup>®</sup> is stable as a drug product in liquid form for several months.

Prof. Dr. Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: *"We are proud to have reached this important milestone in the development of TLR3 ligands, with a unique, highly potent and stable drug product as a better alternative to poly(I:C) and its derivatives. RIBOXXIM<sup>®</sup> is available for pharmaceuticals companies or universities developing clinical applications in immuno-oncology and therapeutic vaccines."*

André Dupont, President of ACCINOVA declared: *"We are proud to be the manufacturer of this innovative experimental drug. This achievement demonstrates the high flexibility of the ACCINOVA model."*

## About RIBOXX PHARMACEUTICALS

RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in immune-oncology and therapeutic vaccines. RIBOXX IP portfolio includes 18 PCT patent families so far, with 8 PCT patents granted in EU and/or Japan.

Contact : Prof. Dr. med. Jacques ROHAYEM - CEO & CSO

RIBOXX PHARMACEUTICALS

[www.riboxx-pharma.com](http://www.riboxx-pharma.com) - +49 351 8336010 - [business.development@riboxx.com](mailto:business.development@riboxx.com)

The development of the industrial GMP manufacturing of RIBOXXIM was supported by the Sächsische Aufbaubank (EFRE Program FKZ 100228307) from the government of Saxony (Germany).

## ABOUT ACCINOV

Accinov is a biomanufacturing centre and provides biotech, pharma and medtech companies with state of the art R&D laboratories (BSL2), cleanrooms (ISO 8-7), GMP manufacturing pilot units & tailored solutions for quality assurance & pharmaceutical support to boost their projects, keep internally their know-how and their IP & manage their facilities in the most flexible way. Accinov's customers have just to plug their projects & play in a full ISO/GMP compliant environment. Accinov has had pharmaceutical establishment status since September 2014 and hosts more than 15 companies and projects, including experimental new drugs production projects. Accinov is part of the infrastructure of Lyonbiopole, the biocluster of the Auvergne-Rhône-Alpes region and is located in Lyon in the heart of the Lyon Gerland Biodistrict.

For more information: [www.accinov.com](http://www.accinov.com)

Follow us on Twitter : [@Accinov](https://twitter.com/Accinov) - on LinkedIn : [www.linkedin.com/company/accinov](http://www.linkedin.com/company/accinov)

**Contact:** Stéphanie Colloud, CEO - [stephanie.colloud@accinov.com](mailto:stephanie.colloud@accinov.com)

Tel: +33-(0)4-3728-7300

## ABOUT LYONBIOPOLE

As a Bio Cluster, Lyonbiopole is the gateway to healthcare innovation in Auvergne-Rhône-Alpes. It's supporting ambitious projects and innovative companies in the healthcare & life sciences' sector. Its aim is to help innovators develop new technologies, products and services in a push toward a more personalized medicine and better treatments for patients.

The cluster's missions are focused around:

- promoting the emergence of innovative R&D collaborative projects;
- supporting SME in areas such as strategic partnerships, access to private investors, expertise and training;
- fostering SME Internationalization and the cluster position at the European and International levels;
- offering access to high-level facilities dedicated to life sciences companies.

In 2016, Lyonbiopole represented a community of 200 members: 6 founding members (Sanofi Pasteur, bioMérieux, Boehringer Ingelheim Animal Health, Becton Dickinson, CEA and Fondation Merieux), 180 innovative companies and 14 Research Centers. Lyonbiopole received the European cluster excellence "Gold Label" by ECEI in 2014 and is HealthTech advisor for within the French Tech network. [www.lyonbiopole.com](http://www.lyonbiopole.com)

**Contact:** Bonne réponse Agency : Marie Tissier – [m.tissier@bonnereponse.fr](mailto:m.tissier@bonnereponse.fr)

Tel: + 33-(0)4-72-40-54-10 / + 33 -(0)6-16-54-55-08